Cargando…

Prognostic and predictive importance of the estrogen receptor coactivator AIB1 in a randomized trial comparing adjuvant letrozole and tamoxifen therapy in postmenopausal breast cancer: the Danish cohort of BIG 1-98

PURPOSE: To evaluate the estrogen receptor coactivator amplified in breast cancer 1 (AIB1) as a prognostic marker, as well as a predictive marker for response to adjuvant tamoxifen and/or aromatase inhibitors, in early estrogen receptor-positive breast cancer. METHOD: AIB1 was analyzed with immunohi...

Descripción completa

Detalles Bibliográficos
Autores principales: Alkner, S., Jensen, M.-B., Rasmussen, B. B., Bendahl, P.-O., Fernö, M., Rydén, L., Mouridsen, H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5668343/
https://www.ncbi.nlm.nih.gov/pubmed/28766132
http://dx.doi.org/10.1007/s10549-017-4416-0
_version_ 1783275654102384640
author Alkner, S.
Jensen, M.-B.
Rasmussen, B. B.
Bendahl, P.-O.
Fernö, M.
Rydén, L.
Mouridsen, H.
author_facet Alkner, S.
Jensen, M.-B.
Rasmussen, B. B.
Bendahl, P.-O.
Fernö, M.
Rydén, L.
Mouridsen, H.
author_sort Alkner, S.
collection PubMed
description PURPOSE: To evaluate the estrogen receptor coactivator amplified in breast cancer 1 (AIB1) as a prognostic marker, as well as a predictive marker for response to adjuvant tamoxifen and/or aromatase inhibitors, in early estrogen receptor-positive breast cancer. METHOD: AIB1 was analyzed with immunohistochemistry in tissue microarrays of the Danish subcohort (N = 1396) of the International Breast Cancer Study Group’s trial BIG 1-98 (randomization between adjuvant tamoxifen versus letrozole versus the sequence of the two drugs). RESULTS: Forty-six percent of the tumors had a high AIB1 expression. In line with previous studies, AIB1 correlated to a more aggressive tumor-phenotype (HER2 amplification and a high malignancy grade). High AIB1 also correlated to higher estrogen receptor expression (80–100 vs. 1–79%), and ductal histological type. High AIB1 expression was associated with a poor disease-free survival (univariable: hazard ratio 1.35, 95% confidence interval 1.12–1.63. Multivariable: hazard ratio 1.29, 95% confidence interval 1.06–1.58) and overall survival (univariable: hazard ratio 1.34, 95% confidence interval 1.07–1.68. Multivariable: hazard ratio 1.25, 95% confidence interval 0.99–1.60). HER2 did not seem to modify the prognostic effect of AIB1. No difference in treatment effect between tamoxifen and letrozole in relation to AIB1 was found. CONCLUSIONS: In a subset of the large international randomized trial BIG 1-98, we confirm AIB1 to be a strong prognostic factor in early breast cancer. Hence, although tumor AIB1 expression does not seem to be useful for the choice of tamoxifen versus an aromatase inhibitor in postmenopausal endocrine-responsive breast cancer, AIB1 is an interesting target for new anti-cancer therapies and further investigations of this biomarker is warranted.
format Online
Article
Text
id pubmed-5668343
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-56683432017-11-16 Prognostic and predictive importance of the estrogen receptor coactivator AIB1 in a randomized trial comparing adjuvant letrozole and tamoxifen therapy in postmenopausal breast cancer: the Danish cohort of BIG 1-98 Alkner, S. Jensen, M.-B. Rasmussen, B. B. Bendahl, P.-O. Fernö, M. Rydén, L. Mouridsen, H. Breast Cancer Res Treat Clinical Trial PURPOSE: To evaluate the estrogen receptor coactivator amplified in breast cancer 1 (AIB1) as a prognostic marker, as well as a predictive marker for response to adjuvant tamoxifen and/or aromatase inhibitors, in early estrogen receptor-positive breast cancer. METHOD: AIB1 was analyzed with immunohistochemistry in tissue microarrays of the Danish subcohort (N = 1396) of the International Breast Cancer Study Group’s trial BIG 1-98 (randomization between adjuvant tamoxifen versus letrozole versus the sequence of the two drugs). RESULTS: Forty-six percent of the tumors had a high AIB1 expression. In line with previous studies, AIB1 correlated to a more aggressive tumor-phenotype (HER2 amplification and a high malignancy grade). High AIB1 also correlated to higher estrogen receptor expression (80–100 vs. 1–79%), and ductal histological type. High AIB1 expression was associated with a poor disease-free survival (univariable: hazard ratio 1.35, 95% confidence interval 1.12–1.63. Multivariable: hazard ratio 1.29, 95% confidence interval 1.06–1.58) and overall survival (univariable: hazard ratio 1.34, 95% confidence interval 1.07–1.68. Multivariable: hazard ratio 1.25, 95% confidence interval 0.99–1.60). HER2 did not seem to modify the prognostic effect of AIB1. No difference in treatment effect between tamoxifen and letrozole in relation to AIB1 was found. CONCLUSIONS: In a subset of the large international randomized trial BIG 1-98, we confirm AIB1 to be a strong prognostic factor in early breast cancer. Hence, although tumor AIB1 expression does not seem to be useful for the choice of tamoxifen versus an aromatase inhibitor in postmenopausal endocrine-responsive breast cancer, AIB1 is an interesting target for new anti-cancer therapies and further investigations of this biomarker is warranted. Springer US 2017-08-01 2017 /pmc/articles/PMC5668343/ /pubmed/28766132 http://dx.doi.org/10.1007/s10549-017-4416-0 Text en © The Author(s) 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Clinical Trial
Alkner, S.
Jensen, M.-B.
Rasmussen, B. B.
Bendahl, P.-O.
Fernö, M.
Rydén, L.
Mouridsen, H.
Prognostic and predictive importance of the estrogen receptor coactivator AIB1 in a randomized trial comparing adjuvant letrozole and tamoxifen therapy in postmenopausal breast cancer: the Danish cohort of BIG 1-98
title Prognostic and predictive importance of the estrogen receptor coactivator AIB1 in a randomized trial comparing adjuvant letrozole and tamoxifen therapy in postmenopausal breast cancer: the Danish cohort of BIG 1-98
title_full Prognostic and predictive importance of the estrogen receptor coactivator AIB1 in a randomized trial comparing adjuvant letrozole and tamoxifen therapy in postmenopausal breast cancer: the Danish cohort of BIG 1-98
title_fullStr Prognostic and predictive importance of the estrogen receptor coactivator AIB1 in a randomized trial comparing adjuvant letrozole and tamoxifen therapy in postmenopausal breast cancer: the Danish cohort of BIG 1-98
title_full_unstemmed Prognostic and predictive importance of the estrogen receptor coactivator AIB1 in a randomized trial comparing adjuvant letrozole and tamoxifen therapy in postmenopausal breast cancer: the Danish cohort of BIG 1-98
title_short Prognostic and predictive importance of the estrogen receptor coactivator AIB1 in a randomized trial comparing adjuvant letrozole and tamoxifen therapy in postmenopausal breast cancer: the Danish cohort of BIG 1-98
title_sort prognostic and predictive importance of the estrogen receptor coactivator aib1 in a randomized trial comparing adjuvant letrozole and tamoxifen therapy in postmenopausal breast cancer: the danish cohort of big 1-98
topic Clinical Trial
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5668343/
https://www.ncbi.nlm.nih.gov/pubmed/28766132
http://dx.doi.org/10.1007/s10549-017-4416-0
work_keys_str_mv AT alkners prognosticandpredictiveimportanceoftheestrogenreceptorcoactivatoraib1inarandomizedtrialcomparingadjuvantletrozoleandtamoxifentherapyinpostmenopausalbreastcancerthedanishcohortofbig198
AT jensenmb prognosticandpredictiveimportanceoftheestrogenreceptorcoactivatoraib1inarandomizedtrialcomparingadjuvantletrozoleandtamoxifentherapyinpostmenopausalbreastcancerthedanishcohortofbig198
AT rasmussenbb prognosticandpredictiveimportanceoftheestrogenreceptorcoactivatoraib1inarandomizedtrialcomparingadjuvantletrozoleandtamoxifentherapyinpostmenopausalbreastcancerthedanishcohortofbig198
AT bendahlpo prognosticandpredictiveimportanceoftheestrogenreceptorcoactivatoraib1inarandomizedtrialcomparingadjuvantletrozoleandtamoxifentherapyinpostmenopausalbreastcancerthedanishcohortofbig198
AT fernom prognosticandpredictiveimportanceoftheestrogenreceptorcoactivatoraib1inarandomizedtrialcomparingadjuvantletrozoleandtamoxifentherapyinpostmenopausalbreastcancerthedanishcohortofbig198
AT rydenl prognosticandpredictiveimportanceoftheestrogenreceptorcoactivatoraib1inarandomizedtrialcomparingadjuvantletrozoleandtamoxifentherapyinpostmenopausalbreastcancerthedanishcohortofbig198
AT mouridsenh prognosticandpredictiveimportanceoftheestrogenreceptorcoactivatoraib1inarandomizedtrialcomparingadjuvantletrozoleandtamoxifentherapyinpostmenopausalbreastcancerthedanishcohortofbig198
AT prognosticandpredictiveimportanceoftheestrogenreceptorcoactivatoraib1inarandomizedtrialcomparingadjuvantletrozoleandtamoxifentherapyinpostmenopausalbreastcancerthedanishcohortofbig198